

The information in the press release is intended for investors.

Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 8, 2024

Today on May 8, 2024 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting (“AGM”) at which the following principal resolutions were passed by the shareholders.

Adoption of income statements and balance sheets for 2024 and discharge from liability

The AGM resolved to adopt the income statements and balance sheets for the company and the group for the financial year 2023. The members of the board of directors and the CEO were discharged from liability for the financial year 2023.

Allocation of earnings

The AGM resolved that no dividend shall be paid for 2023 and that the company’s unappropriated earnings shall be carried forward.

Election of board members and auditors, and fees to the board of directors and auditors

The AGM resolved that the number of members of the board of directors shall be five ordinary members without deputies and that the number of auditors shall be one registered accounting firm.

The AGM re-elected Jan-Eric Österlund, Alain Herrera, Helena Taflin, Lars Lind and Sten Nilsson as members of the board of directors. Jan-Eric Österlund was re-elected as chairman of the board of directors.

The registered accounting firm KPMG AB was re-elected as auditor of the company and it was noted that the authorised accountant Daniel Haglund will be auditor-in-charge.

The AGM resolved that fees to the chairman of the board of directors shall be paid with SEK 550,000, to each of the other members of the board of directors with SEK 250,000, to the chairman of the audit committee with SEK 125,000, to each of the other members of the audit committee with SEK 75,000, to the chairman of the remuneration committee with SEK 75,000 and to each of the other members of the remuneration committee with SEK 50,000.

The AGM resolved that members of the board of directors (in addition to remuneration for expenses relating to travel and accommodation) domiciled in Europe, but outside the Nordic countries, shall receive a remuneration of SEK 7,500 per physical board meeting.

The AGM resolved that remuneration, for services rendered by the auditor of the company, shall be paid in accordance with approved invoice.

Approval of principles for the appointment of the nomination committee

The AGM resolved, in accordance with the nomination committee's proposal, to approve the adjusted principles for the appointment of the nomination committee.

Approval of the board of directors' remuneration report

The AGM resolved to approve the remuneration report for the financial year 2023.

For more information, please contact

Isofol Medical AB (publ)

Jan-Eric Österlund, Chairman of the Board

E-mail: jan-eric@osterlund.co.uk

Phone: +44 7785 368 155

Petter Segelman Lindqvist, Chief Executive Officer

E-mail: petter.s.lindqvist@isofolmedical.com

Phone: +46 (0) 739 60 12 56

The information was submitted for publication, through the agency of the contact persons set out above, at 15:00 CEST on May 8, 2024.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company's drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin's efficacy. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com